CDH1 Gene Mutation, Gastric Cancer, Lobular Breast Carcinoma, Triple Negative Breast Cancer
Conditions
Keywords
Advanced E-cadherin negative gastric cancer, Oestrogen receptor positive lobular breast cancer, Crizotinib, Fulvestrant
Brief summary
The purpose of this study was to find out how effective the combination of crizotinib and fulvestrant was in shrinking lobular breast cancer tumours. The investigators also assessed the side effects of the combination of crizotinib tablets and fulvestrant injections. The side effects and the doses of crizotinib and fulvestrant had already been evaluated in large clinical trials, but this was the first time these two drugs had been combined together.
Detailed description
This clinical study was looking at whether a drug called crizotinib, which is used in some patients with lung cancer, was effective in a sub-type of breast cancer, called lobular breast cancer. As the majority of lobular breast cancers are oestrogen receptor positive (ER+ve), crizotinib was combined with a second drug, fulvestrant, to try to block tumour growth that is driven by oestrogen. Crizotinib targets cancers with genetic changes in two genes called ALK and ROS1. Lung cancers with changes in these genes usually get smaller when treated with crizotinib. Laboratory work at the Institute of Cancer Research has shown that lobular breast cancer cells, due to a mutation in a different gene called CDH1, appear to be similarly affected by crizotinib. Fulvestrant is an oestrogen receptor down regulator and blocks the effects of oestrogen on oestrogen receptor positive (ER+ve) breast cancer cells. Fulvestrant is an established and approved anti-hormone therapy which patients with breast cancers are receiving in the clinic. It is possible that the combination of crizotinib and an anti-oestrogen agent will shrink the tumour(s) more effectively and prevent further growth. Because fulvestrant is only effective in post-menopausal women, if participants had not yet gone through the menopause, participants needed to start (or continue to receive) a monthly injection under the skin to temporarily stop the function of the participant's ovaries to be eligible to take part in the trial. This injection is called goserelin and had to be started at least 4 weeks before the first day of treatment on the trial. The overall aims of this clinical study were to find out: * The proportion of patients whose tumour(s) shrink when they are treated with crizotinib and fulvestrant * The safety and tolerability of fulvestrant in combination with crizotinib, to determine that they can be given together without unacceptable side effects * What the drugs do to the tumours, which will help us decide which patients may benefit from this combination in the future
Interventions
DRUGCrizotinib Oral Capsule [Xalkori]
Crizotinib 250 mg Crizotinib 200mg
DRUGFulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
Sponsors
Pfizer
Breast Cancer Now
Royal Marsden NHS Foundation Trust
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)
Intervention model description
This multi-centre study design will aim to complete recruitment over 18 months from six high volume centres including the Royal Marsden. Parallel recruitment to breast and basket cancer cohorts will take place for this study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Patients with histological diagnosis of E-cadherin negative inoperable or metastatic diffuse gastric cancer (basket cohort), Or inoperable or metastatic triple negative lobular breast cancer (basket cohort) Or inoperable or metastatic CDH1-mutated solid tumour with allele fraction ≥20% (basket cohort) Or recurrent inoperable locally advanced ER positive/HER2 negative lobular breast cancer (breast cohort). Assessment of E-cadherin, ER and HER2 status as per local assessment. \- Lobular breast cancer patients previously treated with at least one prior line of therapy including at least one prior line of hormone therapy for advanced disease, but no more than three prior lines of chemotherapy for advanced disease. Gastric cancer, triple negative lobular breast cancer or CDH1-mutated solid tumour patients previously treated with at least one prior therapy for advanced disease OR relapsing within one year of completing (neo) adjuvant chemotherapy OR unsuitable for chemotherapy in the opinion of the investigator (for example patient choice not to have chemotherapy, or no suitable chemotherapy agent). * Measurable disease (RECIST 1.1) * Haematological and biochemical indices within the ranges shown in protocol. These measurements must be performed within one week (Day -7 to Day 1) before the patient goes in the trial. * Female patients with child-bearing potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial. Both male and female patients of reproductive potential must agree to use two forms of highly effective contraception (see below) for 2 weeks before starting the study treatment, throughout the treatment period and for 90 days after discontinuation of treatment with crizotinib and 2 years after the last dose of fulvestrant. NOTE: it is only considered highly effective if the patient is refraining from sexual intercourse during the entire period of risk associated with the study treatments The oral contraceptive pill may be ineffective when taken with crizotinib so is not an acceptable means of contraception for female patients during this study but can be used by female partners of male patients. * 18 years of age or over with written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up. * World Health Organisation (WHO) performance status 0,1 or 2 * Estimated life expectancy of at least 3 months in the opinion of the investigator * Pre-/peri-menopausal ER+ lobular breast cancer patients must be willing to receive gosarelin injections every 28 days. * Signed and dated informed consent. * Patients willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other procedures.
Exclusion criteria
* Systemic chemotherapy or investigational medicinal products during the previous four weeks, or hormonal therapy within 7 days except luteinizing hormone-releasing hormone (LHRH) analogues for ovarian suppression. Bisphosphonates or RANK ligand antagonists are permitted for the management of bone metastases. * Previous treatment with any agent that inhibits ROS1 * Mixed ductal/lobular breast cancer, unless both ductal and lobular components are CDH1 negative by local assessment * Major surgery (excluding minor procedures, e.g. placement of vascular access) within 4 weeks or radiation therapy within 14 days prior to study entry * Patients with known symptomatic brain metastases requiring steroids, untreated brain metastases or spinal cord compression * Any of the following within 12 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack. Uncontrolled hypertension or cardiac dysrhythmia including atrial fibrillation. * QT interval, corrected \>470 ms or the use of bradycardic agents, drugs which prolong the QT interval and/or anti-arrhythmic agents within 12 days before the first dose of crizotinib or during study treatment. * Use of drugs that are known potent cytochrome P450 (CYP) 3A4 inhibitors or moderate or strong CYP 3A4 inducers within 12 days before the first dose of crizotinib. Us of CYP3A4 substrates with a narrow therapeutic index (such as ciclosporin) is also not permitted within 12 days prior or during the study treatment. * Patients on warfarin. Patients requiring anticoagulation for rate-controlled AF or previous venous thromboembolism should be switched to low-molecular weight heparin. * Known HIV or AIDS-related illness, active infection requiring systemic therapy, or positive HBV or HCV test indicating acute or chronic infection. * Inability or unwillingness to swallow pills, or (for patients receiving fulvestrant) receive IM injections. * Other severe acute or chronic medical condition or psychiatric condition, recent or active suicidal ideation or behaviour, or end stage renal disease on haemodialysis, or laboratory abnormality that may increase the risk associated with study participation or investigational products administration or may interfere with the interpretation of results and, in the judgment of the Investigator, would make the patient inappropriate study entry. * Persisting toxicity related to prior therapy \>Grade 1 (except for stable peripheral neuropathy grade ≤2 or alopecia grade ≤2). * Pregnancy or lactation. * Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or low-grade (Gleason ≤6) prostate cancer. * Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this study. Participation in an observational trial would be acceptable. * Immunocompromised status due to current known active infection with HIV or due to the use of immunosuppressive therapies for other conditions * Known prior or suspected hypersensitivity to investigational products or to any of the excipients. * Patients at risk for gastrointestinal perforation (due to e.g., history of diverticulitis). * Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Breast Cancer Cohort Participants With Confirmed Response Assessed Using RECIST v1.1 | From Day 1 to Progressive Disease, assessed up to end of study (Approximately 57 months) | To assess confirmed response rate by RECIST 1.1 of crizotinib and fulvestrant in advanced E-cadherin negative, ER positive lobular breast cancer. |
| Percentage of Basket Cohort Participants With Confirmed Response Assessed Using RECIST v1.1 | From Day 1 to Progressive Disease, assessed up to end of study (Approximately 57 months) | To assess confirmed response rate (CR/PR outcome) by RECIST 1.1 scan of crizotinib monotherapy in advanced E-cadherin negative, diffuse gastric cancer, triple negative lobular breast cancer or CDH1-mutated solid tumour. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | From Day 1 to 30 days after last dose of study drug, assessed up to end of study (Approximately 57 months) | To assess the overall safety and tolerability of crizotinib with fulvestrant in the breast cancer cohort and as monotherapy in the basket cancer cohort. Toxicity will be assessed by CTCAE (version 4) every 4 weeks during study treatment. Adverse events, including serious adverse events, will be recorded until 30 days after the last dose of study treatment with crizotinib. |
| Progression-free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Both Basket and Breast Cancer Cohorts | From Day 1 to disease progression (PD) or death from any cause, assessed up to end of study (Approximately 57 months) | PFS is defined as the time from baseline treatment to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (\>/=) 20 percent (%) relative increase and \>/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. |
| Assessment of Overall Survival in Each Cohort | From Day 1 to disease progression (PD) or death from any cause, assessed up to end of study (Approximately 57 months) | Overall survival, calculated from day 1 of study treatment to the date of death from any cause. |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Crizotinib Oral Capsule [Xalkori] Monotherapy Arm 1 - Basket (diffuse gastric cancer, triple negative lobular breast cancer and Other CDH1 mutated cancer) cohort. | 6 |
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection Arm 2 - ER positive lobular breast cancer cohort | 27 |
| Total | 33 |
Baseline characteristics
| Characteristic | Crizotinib Oral Capsule [Xalkori] Monotherapy | Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 6 Participants | 9 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 21 Participants | 24 Participants |
| Age, Continuous | 63 years | 57 years | 57 years |
| Cancer Diffuse gastric cancer | 1 Participants | 0 Participants | 1 Participants |
| Cancer ER positive/HER2 negative Lobular breast cancer | 0 Participants | 27 Participants | 27 Participants |
| Cancer other CDH1 Mutated cancer | 0 Participants | 0 Participants | 0 Participants |
| Cancer Triple negative lobular breast cancer | 5 Participants | 0 Participants | 5 Participants |
| Menopausal Status Peri-menopausal | 1 Participants | 4 Participants | 5 Participants |
| Menopausal Status Post-menopausal | 4 Participants | 20 Participants | 24 Participants |
| Menopausal Status Pre-menopausal | 1 Participants | 3 Participants | 4 Participants |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment United Kingdom | 6 participants | 27 participants | 33 participants |
| Sex: Female, Male Female | 6 Participants | 27 Participants | 33 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 6 / 6 | 20 / 27 |
| other Total, other adverse events | 6 / 6 | 27 / 27 |
| serious Total, serious adverse events | 4 / 6 | 5 / 27 |
Outcome results
Primary
Percentage of Basket Cohort Participants With Confirmed Response Assessed Using RECIST v1.1
To assess confirmed response rate (CR/PR outcome) by RECIST 1.1 scan of crizotinib monotherapy in advanced E-cadherin negative, diffuse gastric cancer, triple negative lobular breast cancer or CDH1-mutated solid tumour.
Time frame: From Day 1 to Progressive Disease, assessed up to end of study (Approximately 57 months)
Population: Patients who received at least one cycle of the trial medication and had at least one response (RECIST 1.1 scan) post treatment start. Patients who stopped study treatment before the first response evaluation scan has been performed with clinical progression were included in the disease progression category.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Percentage of Basket Cohort Participants With Confirmed Response Assessed Using RECIST v1.1 | 0 Participants |
Primary
Percentage of Breast Cancer Cohort Participants With Confirmed Response Assessed Using RECIST v1.1
To assess confirmed response rate by RECIST 1.1 of crizotinib and fulvestrant in advanced E-cadherin negative, ER positive lobular breast cancer.
Time frame: From Day 1 to Progressive Disease, assessed up to end of study (Approximately 57 months)
Population: Patients who receive at least one cycle of the trial medication and had at least one response (RECIST 1.1 scan) post treatment start. Patients who stopped study treatment before the first response evaluation scan has been performed with clinical progression were included in the disease progression category.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Percentage of Breast Cancer Cohort Participants With Confirmed Response Assessed Using RECIST v1.1 | 1 Participants |
Secondary
Assessment of Overall Survival in Each Cohort
Overall survival, calculated from day 1 of study treatment to the date of death from any cause.
Time frame: From Day 1 to disease progression (PD) or death from any cause, assessed up to end of study (Approximately 57 months)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Assessment of Overall Survival in Each Cohort | 4.4 months |
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Assessment of Overall Survival in Each Cohort | 17.5 months |
Secondary
Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
To assess the overall safety and tolerability of crizotinib with fulvestrant in the breast cancer cohort and as monotherapy in the basket cancer cohort. Toxicity will be assessed by CTCAE (version 4) every 4 weeks during study treatment. Adverse events, including serious adverse events, will be recorded until 30 days after the last dose of study treatment with crizotinib.
Time frame: From Day 1 to 30 days after last dose of study drug, assessed up to end of study (Approximately 57 months)
Population: Intention to treat (ITT) analysis population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | 6 Participants |
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | 27 Participants |
Secondary
Progression-free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Both Basket and Breast Cancer Cohorts
PFS is defined as the time from baseline treatment to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (\>/=) 20 percent (%) relative increase and \>/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.
Time frame: From Day 1 to disease progression (PD) or death from any cause, assessed up to end of study (Approximately 57 months)
Population: Intention to treat (ITT) analysis population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Progression-free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Both Basket and Breast Cancer Cohorts | 1.8 months |
| Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection | Progression-free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Both Basket and Breast Cancer Cohorts | 1.8 months |